**Name of Journal: *World Journal of Cardiology***

**ESPS Manuscript NO: 25460**

**Manuscript Type: Original Article**

***Basic Study***

**Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure**

Ng TMH *et al*. Norepinephrine regulation of monocytes in heart failure

**Tien MH Ng, Myron L Toews**

**Tien MH Ng, Myron L Toews,** University of Southern California, Los Angeles, CA 90089-9121, United States

**Tien MH Ng,** University of Nebraska Medical Center, Omaha, NE 68198, United States

**Author contributions:** Ng TMH was involved in the design, conduct of the study, statistical analysis, and authorship of the manuscript; Toews ML was involved in the design and assays related to the study.

**Supported by** the American College of Clinical Pharmacy Research Institute.

**Institutional review board statement:** Study was approved by the University of Nebraska Medical Center Institutional Review Board.

**Informed consent statement:** The protocol was approved by the Institutional Review Board of the university. All human subjects gave signed informed consent for their participation.

**Conflict-of-interest statement:** The authors report no conflicts of interest related to the study.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Tien MH Ng, Pharm.D., FHFSA, FCCP, BCPS AQ Cardiology, Associate Professor** of Clinical Pharmacy and Medicine, University of Southern California, School of Pharmacy, 1985 Zonal Ave, Los Angeles, CA 90089-9121, United States. tienng@usc.edu

**Telephone:** +1-323-4421840

**Fax:** +1-323-4421681

**Received:** March 10, 2016

**Peer-review started:** March 15, 2016

**First decision:** April 20, 2016

**Revised:** July 27, 2016

**Accepted:** August 17, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To evaluate the effect of norepinephrine on inflammatory cytokine expression in *ex vivo* human monocytes and monocytic THP-1 cells.

**METHODS:** For human monocyte studies, cells were isolated from 12 chronic heart failure (HF) (66 ± 12 years, New York Heart Association functional class III-IV, left ventricular ejection fraction 22% ± 9%) and 14 healthy subjects (66 ± 12 years). Monocytes (1×106/mL) were incubated with lipopolysaccharide (LPS) 100ng/mL, LPS + norepinephrine (NE) 10-6 M or neither (control) for 4 h. Tumor necrosis factor-alpha (TNFα) and interleukin-10 (IL-10) production were determined by ELISA. Relative contribution of α- and β-adrenergic receptor subtypes on immunomodulatory activity of NE was assessed in LPS-stimulated THP-1 cells incubated with NE, the α-selective agonist phenylephrine (PE), and the β-selective agonist isoproterenol (IPN). NE-pretreated THP-1 cells were also co-incubated with the β-selective antagonist propranolol (PROP), α2-selective antagonist yohimbine (YOH) or the α1-selective antagonist prazosin (PRAZ).

**RESULTS:** Basal TNFα concentrations were higher in HF versus healthy subjects (6.3 ± 3.3 pg/mL *vs* 2.5 ± 2.6 pg/mL, *P =* 0.004). Norepinephrine’s effect on TNFα production was reduced in HF (−41% ± 17% HF *vs* −57% ± 9% healthy, *P =* 0.01), and proportionately with NYHA FC. Increases in IL-10 production by NE was also attenuated in HF (16% ± 18% HF *vs* 38% ± 23% healthy, *P =* 0.012). In THP-1 cells, NE and IPN, but not PE, induced a dose-dependent suppression of TNFα. Co-incubation with NE and antagonists revealed a dose-dependent inhibition of the NE suppression of TNFα by PROP, but not by YOH or PRAZ. Dose-dependent increases in IL-10 production were seen with NE and IPN, but not with PE. This effect was also antagonized by PROP but not by YOH or PRAZ. Pretreatment of cells with IPN attenuated the effects of NE and IPN, but did not induce a response to PE.

**CONCLUSION:** NE regulation of monocyte inflammatory cytokine production may be reduced in moderate-severe HF, and may be mediated through β-adrenergic receptors.

**Key words:** Monocytes; Cytokines; Heart failure; Inflammation

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In evaluating the relationship between sympathetic activation and inflammatory cytokine production in heart failure, we demonstrated that norepinephrine (NE) has reduced ability to suppress the production of the proinflammatory cytokine tumor necrosis factor-alpha, and increase anti-inflammatory interleukin-10, in human isolated monocytes from heart failure compared to healthy subjects. It appears to be mediated through beta-adrenergic, and not alpha-adrenergic, receptors based on monocytic THP-1 cells dose-response experiments. This suggests that the diminished immunomodulatory activity of NE in heart failure is primarily due to altered beta-adrenergic receptor function, and may represent an immunologic mechanism for the positive effects of beta-adrenergic blocking agents.

Ng TMH, Toews ML. Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. *World J Cardiol* 2016; In press

**INTRODUCTION**

The importance of inflammatory cytokines to the pathophysiology of heart failure has been recognized for many years[[1](#_ENREF_1)]. Much of the focus has been on proinflammatory tumor necrosis factor-alpha (TNFα) which has been shown to be cardiodepressant, contributes to exercise intolerance, and modulates apoptosis, oxidative stress and endothelial dysfunction[[2](#_ENREF_2),[3](#_ENREF_3)]. Interleukin-10 (IL-10) antagonizes the inflammatory effects of TNFα. Both TNFα and IL-10 plasma levels are elevated in heart failure patients, although the increase in IL-10 is proportionately less, supporting the notion of a proinflammatory state[[4](#_ENREF_4)].

Pro- and anti-inflammatory cytokine production is regulated by the adrenergic nervous system. Previous studies have demonstrated that β2-, but not β1-, receptor agonists attenuate TNFα expression, while increasing anti-inflammatory interleukin-IL-10 production[[5](#_ENREF_5),[6](#_ENREF_6)]. Conversely, α1,2-adrenergic stimulation results in increased expression of TNFα and reduction in IL-10[[7](#_ENREF_7)]. Under normal physiologic conditions, norepinephrine, an α- and β-agonist, reduces TNFα and enhances IL-10 expression in monocytes exposed to lipopolysaccharide (LPS) and other stimuli[[8](#_ENREF_8)]. However, in heart failure a paradox exists as both catecholamines and TNFα are elevated, which suggests that this negative feedback mechanism may be impaired. The mechanism for the diminished immunomodulatory response to norepinephrine in heart failure is also unknown but could occur secondary to the altered adrenergic expression and function known to exist in the failing heart.

The study purpose was to evaluate whether attenuation of TNFα production and augmentation of IL-10 production by the adrenergic agonist norepinephrine is altered in chronic heart failure compared to healthy, age-matched controls utilizing the model of LPS-stimulated monocytes. In addition, preliminary experiments were undertaken to determine the relative contribution of α- and β-adrenergic receptor subtypes on the immunomodulatory activity of norepinephrine in monocytic THP-1 cells.

**MATERIALS AND METHODS**

***Isolated human monocytes***

Heart failure subjects were recruited from the cardiology clinics and the University Hospital at the University of Nebraska Medical Center. Subjects, male or female, were eligible for inclusion if they had: clinical heart failure (LVEF < 40% on 2D-ECHO or MUGA within last 3 mo), New York Heart Association Functional Class (NYHA FC) III-IV heart failure, and were over 30 years of age. Exclusion criteria included: Primary restrictive or valvular heart failure, acute viral illness or bacterial infection, history of autoimmune disease, concurrent therapy with systemic norepinephrine, known anemia (Hgb < 10 mg/dL) or other contraindication to giving blood. Healthy subjects over the age of 30 were recruited from the University of Nebraska Medical Center through a posting on the university Intranet. All human subjects gave informed consent for their participation. The protocol was approved by the Institutional Review Board of the university.

Monocyte isolation was performed following a standard Nycodenz protocol[[9](#_ENREF_9)], from 12 heart failure [age 66 ± 12 years old, New York Heart Association Functional Class (NYHA FC) 6 III, 6 IV, mean left ventricular ejection fraction 20% ± 10%] and 14 healthy subjects (age 66 ± 12 years). Aliquoted (1 x 106/mL) monocytes were incubated with LPS 100 ng/mL, LPS+norepinephrine 10-6 M or neither (negative control) for 4 h (all reagents from Sigma Chemical Co., Westbury, NY). Previous work demonstrated maximal stimulation of cytokines using the specified reagent concentrations and incubation time. TNFα and IL-10 production were determined by assaying the supernatant using commercially available enzyme-linked immunoassay (ELISA) kits (R&D Systems, Minneapolis, MN).

***THP-1 cells***

THP-1 cells were cultured and assayed in a supplemented RPMI media (ATCC, Manassas, VA). Cells were aliquoted into 1 × 106 cells/mL samples for experiments. Dose-response curves were determined for TNFα and IL-10 production in LPS-stimulated (100 ng/mL) THP-1 cell samples incubated with norepinephrine (10-5 to 10-10 M), the α-selective agonist phenylephrine (PE) (10-6 to 10-10 M) and the β-selective agonist isoproterenol (IPN) (10-5 to 10-10 M). LPS-stimulated THP-1 cells were also co-incubated with a fixed concentration of norepinephrine 10-6 M, which provided maximal effect in agonist experiments, and the β-selective antagonist propranolol (PROP) (10-5 to 10-10 M), α2-selective antagonist yohimbine (YOH) (10-6 to 10-10 M) or the α1-selective antagonist prazosin (PRAZ) (10-6 to 10-10 M), for generation of dose-response curves. TNFα and IL-10 production was assessed as described above. Samples were assayed in duplicate.

***Statistical analysis***

To control for inherent inter-subject differences in constitutive production of cytokines, changes in TNFα and IL-10 concentrations are expressed as percent reduction by norepinephrine + LPS compared to LPS only for each sample. Comparison of percent reduction in TNFα and IL-10 concentrations from isolated monocytes of controls and heart failure subjects was performed by an independent two sample *t*-test. Significance was set at *P* < 0.05. Results are reported as mean ± SD. Comparative effects on cytokine production in THP-1 cells between the different α- and β-adrenergic reagents was assessed *via* visual inspection of the dose-response curves as this was a preliminary study. The statistical methods of this study were reviewed by Mimi Lou, MS (biostatistician) from the University of Southern California School of Pharmacy.

**RESULTS**

***Isolated human monocytes***

Study subject characteristics are described in Table 1. Basal TNFα concentrations (supernatant) were higher in heart failure than healthy subjects (6.3 ± 3.3 pg/mL *vs* 2.5 ± 2.6 pg/mL, *P =* 0.004). Norepinephrine reduction of TNFα production was significantly reduced in monocytes from heart failure subjects (-41% ± 17% HF *vs* -57% ± 9% healthy, *P =* 0.01). Norepinephrine-induced increases in monocyte IL-10 production was also reduced in heart failure (16% ± 18% HF *vs* 38% ± 23% healthy, *P =* 0.012). The diminished response to norepinephrine appeared related to severity of HF, with a greater diminution for both TNFα and IL-10 in NYHA FC IV versus NYHA FC III and controls (Figure 1). A signal for reduced IL-10 response in patients with left ventricular ejection fractions ≤ 20% when compared to those with left ventricular ejection fractions > 20% (7% ± 12 *vs* 25% ± 20%, *P =* 0.07) was also present. There were no differences in cytokine response based on the presence or absence of beta-blocker (BB) therapy (TNFα: -37% ± 17% no BB *vs* -46% ± 17% BB, *P =* 0.9; IL-10: 11% ± 13% no BB *vs* 20% ± 22% BB, *P =* 0.3), or heart failure etiology (TNFα: -41% ± 17% ischemic *vs* -42% ± 18% non-ischemic, *P =* 0.7; IL-10: 20% ± 19% ischemic *vs* 8% ± 15% non-ischemic, *P =* 0.5).

***THP-1 cells***

Norepinephrine and IPN, but not PE, induced a concentration-dependent suppression of TNFα production in cultured monocytic THP-1 cells. Equivalent maximal suppression was achieved with norepinephrine 10-6 M or IPN 10-7 M (Figure 2). Co-incubation of THP-1 cells with LPS, norepinephrine and selective adrenergic receptor antagonists revealed a concentration-dependent inhibition of the norepinephrine suppression of TNFα by PROP, but not by YOH or PRAZ. Maximal blockade of norepinephrine’s effects was obtained at PROP 10-5 M (Figure 3). Concentration-dependent increases in IL-10 production were seen with norepinephrine and IPN, but not with PE (Figure 4). This effect was also antagonized by PROP but not by YOH or PRAZ (Figure 5). Pretreatment of cells with IPN (10-7 M) for 4 h attenuated the effects of norepinephrine and IPN, but pretreatment did not induce a response to PE (data not shown).

**DISCUSSION**

Our preliminary findings suggest norepinephrine’s ability to regulate monocyte inflammatory cytokine production may be reduced in moderate to severe heart failure. The ability of norepinephrine to exert an overall anti-inflammatory effect on the balance of production of TNFα and IL-10 appears to be reduced in proportion to disease severity, as indicated by the a greater diminution of the induced cytokine response in monocytes isolated from NYHA functional class IV as compared to functional class III patients and controls. This is the first report demonstrating monocyte TNFα/IL-10 responsiveness to norepinephrine is diminished in heart failure and provides a novel mechanism to explain increased production of TNFα in heart failure. Our results are consistent with a study demonstrating a reduced inhibitory effect of norepinephrine on TNFα production assessed in whole blood of heart failure patients[[10](#_ENREF_10)]. Our results also agree with other studies demonstrating basal monocytic inflammatory cytokine production is upregulated in chronic heart failure[[11](#_ENREF_11),[12](#_ENREF_12)].

 In addition, based on our experiments in monocytic THP-1 cells, norepinephrine’s immunomodulatory effect in monocytes is likely secondary to activation of β-adrenergic receptors, with no or little involvement of α-adrenergic receptors. This was evidenced by the concentration-dependent reduction of TNFα and augmentation of IL-10 production by norepinephrine and isoproterenol, but not by phenylephrine. The effect of norepinephrine could also be antagonized by β-receptor blockade with propranolol, whereas α1 and α2-blocking agents had no effect. This is consistent with other investigations and provides a plausible mechanism for the diminished cytokine response to norepinephrine observed in heart failure[[13-16](#_ENREF_13)]. Altered β-adrenergic receptor function and expression have been well characterized in the failing heart[[17](#_ENREF_17),[18](#_ENREF_18)]. Beta1-adrenergic receptor density and function is reduced in the failing heart, while beta2-adrenergic receptor expression remains essentially unchanged[[19](#_ENREF_19)]. This shift in importance towards the beta-2-adrenergic receptor would suggest immunomodulatory response to catecholamines would be preserved, however, other pathophysiologic alterations may still occur that change or limit their functionality[[20](#_ENREF_20),[21](#_ENREF_21)]. In addition, norepinephrine is known to have low affinity for beta2-adrenergic receptors, but showed similar maximal effects comparable to isoproterenol[[22](#_ENREF_22),[23](#_ENREF_23)]. Therefore, whether the observed immunomodulatory response to norepinephrine is mediated solely through beta2-adrenergic receptors requires confirmation.

The study has important limitations. The human monocyte experiment sample size is small. Unfortunately we did not have an adequate number of human monocytes to evaluate adrenoreceptor expression between HF and healthy subjects which would strengthen these preliminary findings as THP-1 are a monocytic cell-line but may not be identical to human monocytes. We also did not examine the isolated effects of the receptor antagonists propranolol, yohimbine and prazosin as we are not aware of literature suggesting a direct effect on inflammatory cytokine production, only modulation in a proinflammatory model[[6](#_ENREF_6),[7](#_ENREF_7),[13](#_ENREF_13),[14](#_ENREF_14),[24-27](#_ENREF_24)]. As such, the results of this study are preliminary and should be interpreted as hypothesis generating. Further studies are required to determine whether monocyte production of other cytokines exhibit a similar reduction in response to catecholamine stimulation in heart failure, to fully characterize the mechanism for the observed impaired catecholamine-cytokine response, and to devise pharmacologic strategies to normalize cytokine responsiveness to the adrenergic nervous system.

**ACKOWLEDGEMENTS**

The authors would like to thank Amy Vrana for her help performing assays for this study. The authors would also like to thank Tom Sears, MD for his assistance with identifying heart failure subjects for the study.

**COMMENTS**

***Background***

Inflammation has been recognized as a major contributing factor to the pathophysiology of heart failure with reduced ejection fraction (HFrEF) for many years. However, attempts to improve the prognosis of HFrEF patients by targeting proinflammatory cytokines have failed largely in part to an incomplete understanding of the mechanisms which contribute to the initiation and perpetuation of their expression. Pro- and anti-inflammatory cytokine production is regulated by the adrenergic nervous system. Under normal physiologic conditions, norepinephrine, an α- and β-agonist, reduces tumor necrosis factor-alpha (TNFα) and enhances interleukin-10 expression in monocytes exposed to lipopolysaccharide and other stimuli. However, in HFrEF a paradox exists as both catecholamines and TNFα are elevated, which suggests that this negative feedback mechanism may be impaired.

***Research frontiers***

Heart failure is recognized as a proinflammatory syndrome, and that inflammatory pathways likely contribute to the decline in cardiac function. However, the mechanisms for initiation or persistence of the proinflammatory balance are poorly described and remain an area of active investigation. Clinical trials of agents targeting proinflammatory cytokines have failed to improve long term prognosis of heart failure patients. A major explanation for the failures is an incomplete understanding of mechanisms underlying the proinflammatory state.

***Innovations and breakthroughs***

Although it has been described that catecholamines reduce proinflammatory cytokine production, this is the first study to demonstrate that attenuation of monocyte inflammatory cytokine production by norepinephrine is reduced in cells isolated from heart failure patients compared to healthy individuals.

***Applications***

The findings are mainly descriptive but may represent a novel pathway for the proinflammatory state in patients with heart failure. If alterations in β-adrenergic receptor function is a mechanism for the diminished counter-regulatory response to norepinephrine in heart failure, some of the benefit of beta-adrenergic receptor blockers in heart failure may be due to immunomodulatory or anti-inflammatory effects. These preliminary findings need confirmation in future studies.

***Peer-review***

The manuscript is interesting because it adds new information concerning mechanisms underlying this proinflammatory state.

**REFERENCES**

1. **Mann DL**, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. *Chest* 1994; **105**: 897-904 [PMID: 8131560 DOI: 10.1378/chest.105.3.897]
2. **Torre-Amione G**, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). *J Am Coll Cardiol* 1996; **27**: 1201-1206 [PMID: 8609343 DOI: 10.1016/0735-1097(95)00589-7]
3. **Packer M**. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? *Circulation* 1995; **92**: 1379-1382 [PMID: 7664414 DOI: 10.1161/01.CIR.92.6.1379]
4. **Yamaoka M**, Yamaguchi S, Okuyama M, Tomoike H. Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. *Jpn Circ J* 1999; **63**: 951-956 [PMID: 10614840]
5. **Severn A**, Rapson NT, Hunter CA, Liew FY. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. *J Immunol* 1992; **148**: 3441-3445 [PMID: 1350291]
6. **Guirao X**, Kumar A, Katz J, Smith M, Lin E, Keogh C, Calvano SE, Lowry SF. Catecholamines increase monocyte TNF receptors and inhibit TNF through beta 2-adrenoreceptor activation. *Am J Physiol* 1997; **273**: E1203-E1208 [PMID: 9435537]
7. **Spengler RN**, Allen RM, Remick DG, Strieter RM, Kunkel SL. Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. *J Immunol* 1990; **145**: 1430-1434 [PMID: 2166759]
8. **Chelmicka-Schorr E**, Kwasniewski MN, Czlonkowska A. Sympathetic nervous system and macrophage function. *Ann N Y Acad Sci* 1992; **650**: 40-45 [PMID: 1351378 DOI: 10.1016/0192-0561(92)90082-V]
9. **Bøyum A**. Isolation of human blood monocytes with Nycodenz, a new non-ionic iodinated gradient medium. *Scand J Immunol* 1983; **17**: 429-436 [PMID: 6407099 DOI: 10.1111/j.1365-3083.1983.tb00809.x]
10. **von Haehling S**, Genth-Zotz S, Bolger AP, Kalra PR, Kemp M, Adcock IM, Poole-Wilson PA, Dietz R, Anker SD. Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors. *Am J Cardiol* 2005; **95**: 885-889 [PMID: 15781025 DOI: 10.1016/j.amjcard.2004.12.022]
11. **Conraads VM**, Bosmans JM, Schuerwegh AJ, Goovaerts I, De Clerck LS, Stevens WJ, Bridts CH, Vrints CJ. Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe *vs* mild chronic heart failure. *J Heart Lung Transplant* 2005; **24**: 854-859 [PMID: 15982613 DOI: 10.1016/j.healun.2004.04.017]
12. **Amir O**, Spivak I, Lavi I, Rahat MA. Changes in the monocytic subsets CD14(dim)CD16(+) and CD14(++)CD16(-) in chronic systolic heart failure patients. *Mediators Inflamm* 2012; **2012**: 616384 [PMID: 23226928 DOI: 10.1155/2012/616384]
13. **Nakamura A**, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T. Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. *Cytokine* 1999; **11**: 759-765 [PMID: 10525314 DOI: 10.1006/cyto.1999.0488]
14. **Yoshimura T**, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, Kobayashi J, Yamazaki F, Tanaka H, Inagaki N, Nagai H. Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. *Pharmacology* 1997; **54**: 144-152 [PMID: 9127437 DOI: 10.1159/000139481]
15. **Szabó C**, Haskó G, Zingarelli B, Németh ZH, Salzman AL, Kvetan V, Pastores SM, Vizi ES. Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. *Immunology* 1997; **90**: 95-100 [PMID: 9038718 DOI: 10.1046/j.1365-2567.1997.00137.x]
16. **Abraham E**, Kaneko DJ, Shenkar R. Effects of endogenous and exogenous catecholamines on LPS-induced neutrophil trafficking and activation. *Am J Physiol* 1999; **276**: L1-L8 [PMID: 9887049]
17. **Harding SE**, Brown LA, Wynne DG, Davies CH, Poole-Wilson PA. Mechanisms of beta adrenoceptor desensitisation in the failing human heart. *Cardiovasc Res* 1994; **28**: 1451-1460 [PMID: 8001031 DOI: 10.1093/cvr/28.10.1451]
18. **Drosatos K**, Lymperopoulos A, Kennel PJ, Pollak N, Schulze PC, Goldberg IJ. Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? *Curr Heart Fail Rep* 2015; **12**: 130-140 [PMID: 25475180 DOI: 10.1007/s11897-014-0247-z]
19. **Bristow MR**, Sandoval AB, Gilbert EM, Deisher T, Minobe W, Rasmussen R. Myocardial alpha- and beta-adrenergic receptors in heart failure: is cardiac-derived norepinephrine the regulatory signal? *Eur Heart J* 1988; **9 Suppl H**: 35-40 [PMID: 2844538]
20. **Capote LA**, Mendez Perez R, Lymperopoulos A. GPCR signaling and cardiac function. *Eur J Pharmacol* 2015; **763**: 143-148 [PMID: 25981298 DOI: 10.1016/j.ejphar.2015.05.019]
21. **Lymperopoulos A**, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. *Circ Res* 2013; **113**: 739-753 [PMID: 23989716 DOI: 10.1161/CIRCRESAHA.113.300308]
22. **Mickey JV**, Tate R, Mullikin D, Lefkowitz RJ. Regulation of adenylate cyclase-coupled beta adrenergic receptor binding sites by beta adrenergic catecholamines in vitro. *Mol Pharmacol* 1976; **12**: 409-419 [PMID: 934056]
23. **Lymperopoulos A**, Garcia D, Walklett K. Pharmacogenetics of cardiac inotropy. *Pharmacogenomics* 2014; **15**: 1807-1821 [PMID: 25493572 DOI: 10.2217/pgs.14.120]
24. **Wang J**, Li J, Sheng X, Zhao H, Cao XD, Wang YQ, Wu GC. Beta-adrenoceptor mediated surgery-induced production of pro-inflammatory cytokines in rat microglia cells. *J Neuroimmunol* 2010; **223**: 77-83 [PMID: 20452680 DOI: 10.1016/j.jneuroim.2010.04.006]
25. **Dong J**, Mrabet O, Moze E, Li K, Neveu PJ. Lateralization and catecholaminergic neuroimmunomodulation: prazosin, an alpha1/alpha2-adrenergic receptor antagonist, suppresses interleukin-1 and increases interleukin-10 production induced by lipopolysaccharides. *Neuroimmunomodulation* 2002-2003; **10**: 163-168 [PMID: 12481156 DOI: 10.1159/000067178]
26. **Finck BN**, Dantzer R, Kelley KW, Woods JA, Johnson RW. Central lipopolysaccharide elevates plasma IL-6 concentration by an alpha-adrenoreceptor-mediated mechanism. *Am J Physiol* 1997; **272**: R1880-R1887 [PMID: 9227603]
27. **Johnson JD**, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN, Fleshner M. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. *Neuroscience* 2005; **135**: 1295-1307 [PMID: 16165282 DOI: 10.1016/j.neuroscience.2005.06.090]

**P-Reviewer:** Amiya E, Grignola J, Gong KZ, Iacoviello M, Lymperopoulos A

**S-Editor:** Kong JX **L-Editor: E-Editor:**



**Figure 1 Comparative change in lipopolysaccharide-induced tumor necrosis factor-alpha and interleukin-10** **production in monocytes induced by norepinephrine between heart failure patients and normal controls.** Results expressed as mean ± SD.



**Figure 2 Concentration-dependent changes in lipopolysaccharide-induced tumor necrosis factor-alpha production in monocytic THP-1 cells induced by the α-adrenergic agonist phenylephrine and the β-adrenergic agonist isoproterenol.** Results expressed as mean ± SD.



**Figure 3 Concentration-dependent changes in norepinephrine attenuation of lipopolysaccharide-induced tumor necrosis factor-alpha production in monocytic THP-1 cells blocked by the α1-adrenergic antagonist prazosin, the α2-adrenergic antagonist yohimbine, and the β-adrenergic antagonist propranolol.** Results expressed as mean ± SD.



**Figure 4 Concentration-dependent changes in interleukin-10 production THP-1 cells induced by the α-adrenergic agonist phenylephrine and the β-adrenergic agonist isoproterenol.** Results expressed as mean ± SD.



**Figure 5 Concentration-dependent changes in norepinephrine attenuation of interleukin-10 production in THP-1 cells blocked by the α1-adrenergic antagonist prazosin, the α2-adrenergic antagonist yohimbine, and the β-adrenergic antagonist propranolol.** Results expressed as mean ± SD.

**Table 1 Patient characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| **%** | **Heart failure****(*n* = 12)** | **Healthy subjects****(*n* = 14)** | ***P*-value** |
| Age (yr) | 66 ± 12 | 66 ± 12 | 0.994 |
| Male | 67 | 36 | 0.238 |
| Caucasian ethnicity | 92 | 100 | 0.462 |
| LVEF | 22 ± 9 |  |  |
| Diabetes | 33 | 0 | 0.033 |
| CAD | 50 | 0 | 0.004 |
| Hypertension | 25 | 29 | 1.000 |
| Medications |
| Beta-blocker | 50 | 0 |  |
| ACE inhibitor or ARB | 75 | 7 |  |
| Loop diuretic | 100 | 0 |  |
| ARA | 42 | 0 |  |
| Hydralazine/isosorbide dinitrate | 8 | 0 |  |
| Amiodarone | 50 | 0 |  |
| Digoxin | 50 | 0 |  |

ACE: Angiotensin converting enzyme inhibitor; ARA: Aldosterone receptor blocker; ARB: Angiotensin receptor blocker; CAD: Coronary artery disease; LVEF: Left ventricular ejection fraction.